Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

BM 13505

Known as: BM 13.505, BM-13505 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1997
1997
The antithrombotic effect of desethyl KBT-3022, which is the main active metabolite of the new antiplatelet agent, KBT-3022… Expand
1995
1995
The effects of platelet-activating factor (PAF) on vascular resistance and capillary permeability were studied in the isolated… Expand
1994
1994
1 The objectives of the present experiments were to assess the role of ETA receptors in mediating endothelin‐1 (ET‐1)‐induced… Expand
1993
1993
The antithrombotic effects of the thromboxane (TX) A2-receptor antagonist and aspirin were determined using a photochemically… Expand
1993
1993
The effects of KW-3635 (sodium (E)-11-[2-(5,6-dimethyl-1-benzimidazolyl) ethylidene]-6,11-dihydrodibenz-[b,e]oxepine-2… Expand
Highly Cited
1992
Highly Cited
1992
The purpose of the present experiments was to study the effects of endothelin-1 (ET-1) on vascular permeability and the… Expand
1992
1992
Thromboxane A2/prostaglandin H2 (TXA2/PGH2) receptors were characterized in rat vascular smooth muscle cells (VSMC). The specific… Expand
1989
1989
The ability of BM-13505, 4-[2-(4-chlorobenzenesulfonylamino) ethyl]-benzene acetic acid), a specific thromboxane/endoperoxide… Expand
1988
1988
  • N. Aoki, A. Lefer
  • Methods and findings in experimental and clinical…
  • 1988
  • Corpus ID: 22268136
Splanchnic artery occlusion (SAO) followed by release of the occlusive clamps produces circulatory shock characterized by an… Expand
1986
1986
The new specific thromboxane receptor antagonist, BM-13505, was infused intravenously (1 mg/kg bolus and 1 mg/kg hr continuous… Expand